These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 14694102)

  • 1. Role of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribonucleosides.
    Komazin G; Townsend LB; Drach JC
    J Virol; 2004 Jan; 78(2):710-5. PubMed ID: 14694102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56.
    Krosky PM; Underwood MR; Turk SR; Feng KW; Jain RK; Ptak RG; Westerman AC; Biron KK; Townsend LB; Drach JC
    J Virol; 1998 Jun; 72(6):4721-8. PubMed ID: 9573236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27.
    Komazin G; Ptak RG; Emmer BT; Townsend LB; Drach JC
    J Virol; 2003 Nov; 77(21):11499-506. PubMed ID: 14557635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human cytomegalovirus resistance to deoxyribosylindole nucleosides maps to a transversion mutation in the terminase subunit-encoding gene UL89.
    Gentry BG; Phan Q; Hall ED; Breitenbach JM; Borysko KZ; Kamil JP; Townsend LB; Drach JC
    Antimicrob Agents Chemother; 2015 Jan; 59(1):226-32. PubMed ID: 25348532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product.
    Underwood MR; Harvey RJ; Stanat SC; Hemphill ML; Miller T; Drach JC; Townsend LB; Biron KK
    J Virol; 1998 Jan; 72(1):717-25. PubMed ID: 9420278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirus.
    Krosky PM; Borysko KZ; Nassiri MR; Devivar RV; Ptak RG; Davis MG; Biron KK; Townsend LB; Drach JC
    Antimicrob Agents Chemother; 2002 Feb; 46(2):478-86. PubMed ID: 11796361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds.
    Chou S
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus.
    Evers DL; Komazin G; Shin D; Hwang DD; Townsend LB; Drach JC
    Antiviral Res; 2002 Oct; 56(1):61-72. PubMed ID: 12323400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.
    Biron KK; Harvey RJ; Chamberlain SC; Good SS; Smith AA; Davis MG; Talarico CL; Miller WH; Ferris R; Dornsife RE; Stanat SC; Drach JC; Townsend LB; Koszalka GW
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2365-72. PubMed ID: 12121906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products.
    Buerger I; Reefschlaeger J; Bender W; Eckenberg P; Popp A; Weber O; Graeper S; Klenk HD; Ruebsamen-Waigmann H; Hallenberger S
    J Virol; 2001 Oct; 75(19):9077-86. PubMed ID: 11533171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity.
    Champier G; Couvreux A; Hantz S; Rametti A; Mazeron MC; Bouaziz S; Denis F; Alain S
    Antivir Ther; 2008; 13(5):643-54. PubMed ID: 18771048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
    Piret J; Boivin G
    Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of the putative human cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides.
    Dittmer A; Drach JC; Townsend LB; Fischer A; Bogner E
    J Virol; 2005 Dec; 79(23):14660-7. PubMed ID: 16282466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in DNA packaging genes and sensitivity to benzimidazole ribonucleosides between human cytomegalovirus strains AD169 and Towne.
    Krosky PM; Ptak RG; Underwood MR; Biron KK; Townsend LB; Drach JC
    Antivir Chem Chemother; 2000 Sep; 11(5):349-52. PubMed ID: 11142634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms.
    Evers DL; Komazin G; Ptak RG; Shin D; Emmer BT; Townsend LB; Drach JC
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3918-27. PubMed ID: 15388453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of acetylated, tetrahalogenated benzimidazole D-ribonucleosides with enhanced activity against human cytomegalovirus.
    Hwang JS; Kregler O; Schilf R; Bannert N; Drach JC; Townsend LB; Bogner E
    J Virol; 2007 Nov; 81(21):11604-11. PubMed ID: 17728228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dramatic effects of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside on the genome structure, packaging, and egress of guinea pig cytomegalovirus.
    Nixon DE; McVoy MA
    J Virol; 2004 Feb; 78(4):1623-35. PubMed ID: 14747528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Guinea pig cytomegalovirus resistant to the DNA maturation inhibitor BDCRB.
    Ourahmane A; Sauer A; Nixon DE; Murphy C; Mondello M; Douglass Chiu E; Siegmund S; Wang JB; McVoy MA
    Antiviral Res; 2018 Jun; 154():44-50. PubMed ID: 29649495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies designed to increase the stability and antiviral activity (HCMV) of the active benzimidazole nucleoside, TCRB.
    Townsend LB; Gudmundsson KS; Daluge SM; Chen JJ; Zhu Z; Koszalka GW; Boyd L; Chamberlain SD; Freeman GA; Biron KK; Drach JC
    Nucleosides Nucleotides; 1999; 18(4-5):509-19. PubMed ID: 10432642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action.
    Reefschlaeger J; Bender W; Hallenberger S; Weber O; Eckenberg P; Goldmann S; Haerter M; Buerger I; Trappe J; Herrington JA; Haebich D; Ruebsamen-Waigmann H
    J Antimicrob Chemother; 2001 Dec; 48(6):757-67. PubMed ID: 11733458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.